Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Particulate form
Reexamination Certificate
2005-07-12
2005-07-12
Guzo, David (Department: 1636)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Particulate form
C424S093100, C424S093200, C435S455000, C435S320100
Reexamination Certificate
active
06916490
ABSTRACT:
The present invention contemplates in part coacervates in which a bioactive substance and delivery agent are encapsulated therein for controlled release. In certain embodiments, said bioactive substance and delivery agent are a viral vector and virus, respectively. Processes for preparing and using coacervates of the present invention are described.
REFERENCES:
patent: 4325937 (1982-04-01), Spence et al.
patent: 4376113 (1983-03-01), Suglia et al.
patent: 4741872 (1988-05-01), De Luca et al.
patent: 4818542 (1989-04-01), DeLuca et al.
patent: 5407609 (1995-04-01), Tice et al.
patent: 5531925 (1996-07-01), Landh et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5626863 (1997-05-01), Hubbell et al.
patent: 5759582 (1998-06-01), Leong et al.
patent: 5783567 (1998-07-01), Hedley et al.
patent: 5861159 (1999-01-01), Pardoll et al.
patent: 5942253 (1999-08-01), Gombotz et al.
patent: 5972707 (1999-10-01), Roy et al.
patent: 6008202 (1999-12-01), Huang et al.
patent: 6025337 (2000-02-01), Truong et al.
patent: 6159502 (2000-12-01), Russell-Jones et al.
patent: 248 531 (1987-12-01), None
patent: 467 389 (1992-01-01), None
patent: 467 389 (1992-01-01), None
patent: 635 261 (1995-01-01), None
patent: WO 94/23699 (1994-10-01), None
patent: WO 94/23738 (1994-10-01), None
patent: WO 95/03789 (1995-02-01), None
patent: WO 95/20660 (1995-08-01), None
patent: WO 95/24929 (1995-09-01), None
patent: WO 95/35097 (1995-12-01), None
patent: WO 96/00295 (1996-01-01), None
patent: WO 96 026 55 (1996-02-01), None
patent: WO 96/29998 (1996-10-01), None
patent: WO 98/01162 (1998-01-01), None
patent: WO 98/30207 (1998-07-01), None
Leitner, W. et al.; DNA and RNA-based vaccines: principles, progress and prospects, 2000, Vaccine 18: 765-777.
McCluskie, M. et.al.; Routeand method of delivery olf DNA vaccine inf.luence immune responses in mice and non-human primates, 1999I Mol. Med. 5: 287-300.
Casey, G. et.al.; Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene; 1991. Oncogene 6: 1791-1797.
Miller, N. et al.; Targeted vectors for gene therapy, 1995, FASEB J. 9: 190-199.
Deonarian. M.; Ligand-targeted receptor-mediated vectors for gene therapy, 1998, Exp. Opin. Ther. Patents 8: 53-69.
Verma, I.; Gene therapy-promises. problems and prospects, 1997; Nature 389: 239-242.
Chattergoon, M.: Genetic immunization: a new era in vaccines and immune therapeutics. 1997: FASEB J. 11: 753-763.
Narayani & Rao. J. Biomater. Sci. Polymer Edn. 7:39-48, 1995.
Kalyanasundaram et al. Cancer gene therapy 4:S23, 1997.
Kalyanasundaram et al. Cancer gene therapy 6:107-112, 1999.
Beer et al. Adv. drug delivery reviews 27:59-66, 1997.
Dang et al. Clin. Cancer Res. 5:471-474, 1999.
Wivel & Wilson. Hematol. Oncol. Clin. North Am. 12:483-501, 1998.
Eck & Wilson. Gene-based therapy in Goodman & Gilman's The pharmacological basis of therapeutics, Ninth edition, pp. 77-101, 1996.
Leong et al. J. Controlled Rel. 53: 183-193, 1998.
Kalyanasundaram et al., “Coacervate microspheres as carriers of recombinant adenoviruses,” Cancer Gene Therapy, 6:(2)107-112 (1999).
Kalyanasundram et al., “Recombinant adenovirus can be encapsulated and released from coacervate microspheres in a time-dependent fashion,” Cancer Gene Therapy, 4(6) S23 (1997), Abstract.
Alpar et al., “Potential of Particulate Carrier for the Mucosal Delivery of DNA Vaccines”. Biochemical Society Transactions 25(2): 347 (1997).
Heard, R. “HLA and Autoimmune Disease”, HLA & Disease, pp. 123-151 (1994).
Leong et al., “Polymeric Controlled Drug Delivery”, Advanced Drug Delivery Reviews. 199-233 (1987).
O'Hagan, Derek T., “Recent Advances in Vaccine Adjuvants for Systemic and Mucosal Administration”, J. Pharm. Pharmacol. 49: 1-10 (Sep. 15, 1997).
Tomlinson et al., “Controllable Gene Therapy Pharmaceutics of non-viral Gene Delivery Systems”, Journal of Controlled Release 39: 357-372 (1996).
Weiner et al., “Genetics Vaccines”, Scientific American pp. 50-57 (Jul. 1999).
Hedley, M. Genetic Modulation of Antigen Presentation, MHC Molecules: Expression Assembly and Function, Ch. 17, pp. 281-293: Editors: Robert G. Urban and Roman M. Chicz: Published by R. G. Landes & Co. (1996).
Garver Robert I.
Kalyanasundaram Subramanian
Leong Kam W.
Fenton, Esq. Gillian M.
Foley & Hoag LLP
Guzo David
Nguyen Quang
The Johns Hopkins University
LandOfFree
Controlled release of bioactive substances does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Controlled release of bioactive substances, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Controlled release of bioactive substances will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3431522